Lineage Cell Therapeutics' Registration Statement Effective March 23, 2026

Ticker: LCTX · Form: EFFECT · Filed: Mar 24, 2026 · CIK: 0000876343

Lineage Cell Therapeutics, Inc. EFFECT Filing Summary
FieldDetail
CompanyLineage Cell Therapeutics, Inc. (LCTX)
Form TypeEFFECT
Filed DateMar 24, 2026
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: registration-statement, capital-raise, regulatory-approval

TL;DR

**Lineage Cell Therapeutics just got SEC approval to sell more stock.**

AI Summary

The SEC has declared the registration statement for Lineage Cell Therapeutics, Inc. (CIK: 0000876343) effective as of March 23, 2026. This means the company can now proceed with offering and selling the securities described in their File No. 333-294202. For investors, this effectiveness is a green light for the company to potentially raise capital, which could fund their biological product development (SIC: 2836) but also might lead to share dilution depending on the offering's structure.

Why It Matters

This filing signals that Lineage Cell Therapeutics can now move forward with its plans to offer securities, potentially impacting the company's capital structure and future growth prospects.

Risk Assessment

Risk Level: medium — While effectiveness allows capital raising, the details of the offering (price, number of shares) are unknown and could dilute existing shareholders.

Analyst Insight

Investors should now look for subsequent filings (like a prospectus supplement or 424B) from Lineage Cell Therapeutics to understand the specific terms (e.g., price, number of shares) of the securities offering that this effectiveness enables, as these details will determine the actual impact on the stock.

Key Players & Entities

  • Lineage Cell Therapeutics, Inc. (company) — the filer of the EFFECT filing
  • 0000876343 (company) — the CIK (Central Index Key) for Lineage Cell Therapeutics, Inc.
  • March 23, 2026 (date) — the effectiveness date of the registration statement
  • 333-294202 (dollar_amount) — the File No. for the registration statement that became effective

FAQ

What does an 'EFFECT' filing mean for Lineage Cell Therapeutics, Inc.?

An 'EFFECT' filing, specifically the Notice of Effectiveness (SEC Accession No. 9999999995-26-000908), means that the SEC has declared Lineage Cell Therapeutics, Inc.'s registration statement (File No. 333-294202) effective as of March 23, 2026. This allows the company to legally offer and sell the securities described in that registration statement to the public.

When was the registration statement for Lineage Cell Therapeutics, Inc. declared effective?

The registration statement for Lineage Cell Therapeutics, Inc. was declared effective on March 23, 2026, as stated in the filing's 'Effectiveness Date' field.

Filing Stats: 34 words · 1 min read · ~1 pages · Grade level 9.2 · Accepted 2026-03-24 00:15:15

Filing Documents

From the Filing

Notice of Effectiveness UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Notice of Effectiveness Effectiveness Date: March 23, 2026 4:30 P.M. Form: S-3 CIK: Company Name: Lineage Cell Therapeutics, Inc. File Number: 333-294202

View Full Filing

View this EFFECT filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.